英文名称 | Crizotinib hydrochloride | PF-02341066 hydrochloride |
---|---|
中文名称 | 盐酸克里唑替尼 |
CAS号 | 1415560-69-8 |
分子式 | C21H23Cl3FN5O |
分子量 | 486.80 |
外观 | Yellow to brown powder |
储存条件 | 4°C, sealed storage, away from moisture |
英文名称 | Crizotinib hydrochloride | PF-02341066 hydrochloride |
---|---|
中文名称 | 盐酸克里唑替尼 |
CAS号 | 1415560-69-8 |
分子式 | C21H23Cl3FN5O |
分子量 | 486.80 |
外观 | Yellow to brown powder |
储存条件 | 4°C, sealed storage, away from moisture |
Crizotinib HCl (formerly known as PF-02341066 hydrochloride; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK, with IC50 values of 11 nM and 24 nM in assays involving cells, respectively. In the US, crizotinib is licensed for the treatment of non-small cell lung cancer (NSCLC). It is also being investigated in clinical trials for safety and effectiveness in the treatment of neuroblastoma, anaplastic large cell lymphoma, and other advanced solid tumors in both adults and children. Crizotinib inhibits the activation of the MET signaling pathway and the membrane receptor MET, which in susceptible tumor cell populations may prevent tumor cell growth, migration, invasion, and angiogenesis.
PMID: 17483355 DOI: 10.1158/0008-5472.CAN-06-4443
PMID: 21812414 DOI: 10.1021/jm2007613
Mol Cancer Ther. 2007, 6(12 Pt 1), 3314-3322.